Pharmacogenomic Investments By Rx Firms May Lead To End Of Blockbusters
Executive Summary
The level of investment by pharmaceutical companies in pharmacogenomics will reflect the industry's comfort with moving away from broadly labeled blockbuster products to more narrowly focused medicines, Ernst & Young suggested in its annual report on the European life sciences industry.